Roquette to Showcase Pharmaceutical Excipients and Drug Delivery Solutions at CPHI Milan 2026
Roquette, a global provider of pharmaceutical excipients, drug delivery technologies and biopharmaceutical solutions, will showcase its broad portfolio and technical expertise at CPHI Milan 2026 in Italy. The company will welcome pharmaceutical and life sciences professionals at Booth 1A18 in the Excipients Hall, where it plans to highlight technologies designed to support formulation development, drug delivery, manufacturing performance and biopharmaceutical processing.
CPHI Milan is expected to bring together pharmaceutical manufacturers, developers, suppliers and other industry stakeholders from across the global healthcare and life sciences ecosystem. For Roquette, the event will provide an opportunity to demonstrate how its portfolio of excipients and drug delivery solutions can help address formulation challenges across a range of pharmaceutical applications.
At the 2026 event, Roquette will place particular emphasis on its end-to-end capabilities, spanning pharmaceutical excipients, patient-focused drug delivery, hard capsules, specialized formulation ingredients and biopharmaceutical processing solutions. The company’s portfolio includes established brands such as METHOCEL™ cellulose ethers, PEARLITOL® mannitol, Avicel® microcrystalline cellulose, POLYOX™ polyethylene oxide, KLEPTOSE® cyclodextrins and LYCADEX® pyrogen-free dextrose monohydrate.
The company will also feature Qualicaps™ by Roquette hard capsules and its alginate portfolio made from sustainably sourced seaweed. In addition, Roquette will highlight solutions supporting biopharmaceutical development and manufacturing, including technologies for upstream processing, downstream efficiency and formulation.
Broad Portfolio Designed for Pharmaceutical Formulation
Pharmaceutical excipients play an important role in drug development and manufacturing. While active pharmaceutical ingredients are responsible for the therapeutic effect of a medicine, excipients can influence characteristics such as stability, manufacturability, dosage-form performance, drug release and patient acceptability.
Roquette’s CPHI Milan portfolio presentation will demonstrate the company’s focus on providing ingredients and technologies that can be incorporated into different dosage forms and development strategies.
Among the featured products will be METHOCEL™ cellulose ethers, which are used in pharmaceutical formulations for applications that can include binding, controlled release and other formulation functions.
The company will also showcase PEARLITOL® mannitol, an excipient used in pharmaceutical formulations where properties such as compressibility, mouthfeel and processing performance can be important.
Another featured brand will be Avicel® microcrystalline cellulose, a widely used pharmaceutical excipient associated with applications including direct compression and tablet formulation.
Roquette will additionally present POLYOX™ polyethylene oxide, which can support specialized drug delivery and controlled-release formulations. The portfolio also includes KLEPTOSE® cyclodextrins, which can be used in formulation development to address challenges related to drug solubility and delivery.
For applications involving specialized pharmaceutical manufacturing requirements, Roquette will highlight LYCADEX® pyrogen-free dextrose monohydrate.
By bringing these products together at CPHI Milan, Roquette aims to demonstrate how its portfolio can support pharmaceutical companies across different stages of formulation development and manufacturing.
Focus on Patient-Centric Drug Delivery
Patient needs are increasingly influencing pharmaceutical development, with drug manufacturers seeking dosage forms and delivery approaches that can improve convenience, usability and overall treatment experience.
Roquette said its presence at CPHI Milan will reflect this broader focus on patient-centric pharmaceutical development. The company’s portfolio includes solutions intended to help formulators address technical requirements while also considering factors that can influence the patient experience.
Hard capsules will be an important part of the company’s showcase. Visitors to Booth 1A18 will have an opportunity to preview the newest addition to the Qualicaps™ portfolio.
According to Roquette, the new offering has been developed to expand the range of hard capsule options available to pharmaceutical manufacturers while maintaining the quality and reliability associated with Qualicaps™ by Roquette.
Hard capsules remain an important dosage form for pharmaceutical products, offering manufacturers flexibility in formulation and product development. The addition to the Qualicaps portfolio is expected to give pharmaceutical companies another option as they evaluate capsule-based delivery systems.
Roquette’s experts will be available throughout the exhibition to discuss how capsule technologies and other drug delivery solutions can be incorporated into pharmaceutical development programs.
Supporting Oral Solid Dosage Development
Oral solid dosage forms remain a major area of pharmaceutical manufacturing, and Roquette will dedicate part of its CPHI Milan presence to solutions supporting this category.
Tablets and capsules can present a range of formulation and manufacturing challenges, including powder flow, compressibility, dissolution, stability and controlled release. Selecting appropriate excipients can be an important part of addressing these challenges.
Roquette’s portfolio brings together multiple excipient technologies intended for different formulation functions. The company said its specialists will be available to discuss formulation strategies and potential solutions for oral solid dosage applications.
The presence of METHOCEL, PEARLITOL, Avicel, POLYOX and KLEPTOSE at the booth reflects the breadth of Roquette’s offering for developers working on conventional and more specialized oral formulations.
Rather than focusing on a single ingredient or dosage form, the company plans to demonstrate an integrated portfolio approach that can support pharmaceutical manufacturers as they move from formulation development toward commercial manufacturing.
Parenteral and Biopharmaceutical Applications
Roquette’s CPHI Milan showcase will extend beyond oral pharmaceutical formulations to include parenteral and biopharmaceutical applications.
Biopharmaceutical manufacturing requires specialized solutions across multiple stages of the production process. Roquette will highlight technologies designed to support upstream processing, downstream efficiency and formulation activities.
Upstream processing is associated with the production of biological molecules and can require carefully selected materials and process solutions. Downstream processing involves purification and recovery steps that are critical to achieving the required quality and consistency of biopharmaceutical products.
Formulation is another important stage, particularly for biological medicines that can have complex stability and delivery requirements.
Roquette said its biopharma portfolio is intended to support customers across these different stages, reflecting the company’s broader approach to pharmaceutical and biopharmaceutical development.
The company will use CPHI Milan to connect these capabilities with its wider excipient and drug delivery portfolio, providing visitors with an opportunity to discuss potential solutions based on their individual development and manufacturing needs.
Alginate Portfolio and Sustainable Sourcing
Another component of Roquette’s showcase will be its alginate portfolio, which is derived from sustainably sourced seaweed.
Alginate is a naturally derived polysaccharide with properties that can make it useful in pharmaceutical and other healthcare applications. Its inclusion in Roquette’s CPHI portfolio reflects the company’s interest in providing ingredient options that combine functional performance with considerations related to sourcing.
As pharmaceutical companies increasingly evaluate raw material sourcing and sustainability alongside formulation performance, ingredient provenance can become an important part of supplier discussions.
Roquette’s sustainably sourced seaweed-based alginate offering will therefore form part of the company’s broader portfolio story at CPHI Milan, alongside its established pharmaceutical excipients and drug delivery technologies.
Interactive Experience for CPHI Milan Visitors
In addition to its technical product presentations, Roquette will offer an interactive experience at Booth 1A18.
The company plans to create an interactive zone where visitors can explore its excipient solutions through digital experiences. The activity is designed to provide an engaging way for attendees to learn more about Roquette’s pharmaceutical portfolio while also offering opportunities to win prizes.
The interactive component will complement the company’s technical discussions, allowing visitors to engage with Roquette’s products and capabilities in a less traditional exhibition format.
For pharmaceutical professionals attending CPHI Milan, the booth will provide access to Roquette specialists who can discuss formulation development, drug delivery and biopharmaceutical applications directly.
Technical Expertise and Collaborative Approach
Roquette said its CPHI Milan presence will emphasize not only its products but also the technical expertise supporting their use.
Formulation challenges can vary significantly depending on the active pharmaceutical ingredient, dosage form, manufacturing process, target patient population and desired product characteristics. As a result, pharmaceutical developers often require more than access to individual excipients.
Technical support can be important in evaluating ingredient compatibility, optimizing formulations, understanding processing behavior and identifying approaches that can help address development challenges.
Roquette intends to position its technical specialists as part of that collaborative process at CPHI Milan.
“Pharmaceutical innovation is ultimately measured by the difference it makes in patients’ lives,” said Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business Unit.
“At CPHI Milan, we will show how the right combination of science, technology and partnership can turn complex formulation challenges into solutions that are more effective, reliable and meaningful for patients,” Bergerone added.
Her comments reflect Roquette’s emphasis on combining scientific expertise with customer collaboration. The company is expected to use the event to discuss how its ingredients, delivery technologies and technical support can contribute to pharmaceutical development programs.
Solutions Across Multiple Pharmaceutical Applications
Roquette’s experts at Booth 1A18 will be available to discuss solutions across four major application areas: oral solid dosage, parenteral products, drug delivery and biopharmaceutical applications.
For oral solid dosage manufacturers, discussions may center on excipients supporting tablet and capsule formulation, processing and drug release.
For parenteral developers, the company’s portfolio includes materials intended to support specialized pharmaceutical formulations and manufacturing requirements.
In drug delivery, Roquette will highlight technologies that can help address formulation and delivery challenges, including its cellulose ether, polyethylene oxide and cyclodextrin offerings.
Meanwhile, its biopharmaceutical solutions will address needs across upstream processing, downstream operations and formulation.
This broad application focus illustrates Roquette’s strategy of providing pharmaceutical customers with access to multiple technologies and technical capabilities through a single portfolio.
Roquette’s CPHI Milan 2026 Presence
Roquette’s participation in CPHI Milan 2026 will provide an opportunity for the company to engage with pharmaceutical manufacturers, formulation scientists, drug developers and biopharmaceutical professionals from around the world.
At Booth 1A18 in the Excipients Hall, visitors will be able to explore the company’s portfolio of pharmaceutical excipients, drug delivery technologies, hard capsules, alginate-based solutions and biopharmaceutical offerings.
Key brands featured at the event will include METHOCEL™ cellulose ethers, PEARLITOL® mannitol, Avicel® microcrystalline cellulose, POLYOX™ polyethylene oxide, KLEPTOSE® cyclodextrins, LYCADEX® pyrogen-free dextrose monohydrate and Qualicaps™ by Roquette hard capsules.
The company will also introduce visitors to the newest addition to its Qualicaps portfolio and provide opportunities to learn more about its sustainably sourced seaweed alginate solutions.
Beyond individual products, Roquette’s presence is designed to demonstrate how excipient selection, drug delivery technology, formulation expertise and biopharmaceutical capabilities can work together to support pharmaceutical innovation.
As pharmaceutical development continues to evolve toward more complex formulations, advanced delivery technologies and patient-focused dosage forms, suppliers with broad portfolios and technical capabilities can play an important role in helping manufacturers address development and production challenges.
Through its CPHI Milan 2026 showcase, Roquette will highlight its approach to these evolving requirements while giving industry professionals direct access to its scientific and technical experts. The company’s combination of pharmaceutical excipients, drug delivery solutions, capsule technologies and biopharmaceutical capabilities will form the foundation of its participation at the global industry event.
About Roquette
Roquette is a global leader in sustainable plant-based solutions, driving innovation and strong partnerships that are shaping the future of nutrition, health, and bioindustry.
The company harnesses natural resources such as wheat, corn, seaweed, and cellulose to craft high-performance ingredients used in everyday foods, oral medications, advanced biopharmaceuticals, and a range of bio-based products.
A family-owned company with over 90 years of expertise and 11,000 employees, Roquette serves clients in over 150 countries and is committed to creating lasting value for customers, patients, consumers, and society.
Together, we turn the potential of nature into the essentials of life.